Thus, several Chk1/Chk2 inhibitors, including XL-844, AZD7762, and PF00477736, which potentiate the effects of DNA-damaging therapies by abrogating DNA damage-induced cell cycle arrest, have entered clinical trials for cancer therapy in combination with chemotherapeutic drugs (215). The gene discussed is CHEK2; the disease is cancer.